Identification of an IgG CDR sequence contributing to co‐purification of the host cell protease cathepsin D

Recombinant therapeutic monoclonal antibodies (mAbs) must be purified from host cell proteins (HCPs), DNA, and other impurities present in Chinese hamster ovary (CHO) cell culture media. HCPs can potentially result in adverse clinical responses in patients and, in specific cases, have caused degradation of the final mAb product. As reported previously, residual traces of cathepsin D caused particle formation in the final product of mAb‐1. The current work was focused on identification of a primary sequence in mAb‐1 responsible for the binding and consequent co‐purification of trace levels of CHO cathepsin D. Surface plasmon resonance (SPR) was used to detect binding between immobilized CHO cathepsin D and a panel of mAbs. Out of 13 mAbs tested, only mAb‐1 and mAb‐6 bound to cathepsin D. An LYY motif in the HC CDR2 was common, yet unique, to only these two mAbs. Mutation of LYY to AAA eliminated binding of mAb‐1 to cathepsin D providing confirmation that this sequence motif was involved in the binding to CHO cathepsin D. Interestingly, the binding between mAb‐1 and cathepsin D was weaker than that of mAb‐6, which may be related to the fact that two aspartic acid residues near the LYY motif in mAb‐1 are replaced with neutral serine residues in mAb‐6. © 2016 American Institute of Chemical Engineers Biotechnol. Prog., 33:140–145, 2017

[1]  K. Inouye,et al.  Pepsin digestion of a mouse monoclonal antibody of IgG1 class formed F(ab')(2) fragments in which the light chains as well as the heavy chains were truncated. , 2001, Journal of biochemical and biophysical methods.

[2]  Wei Wang,et al.  Impact of residual impurities and contaminants on protein stability. , 2014, Journal of pharmaceutical sciences.

[3]  John W. Erickson,et al.  Conformational switching in an aspartic proteinase , 1998, Nature Structural Biology.

[4]  Michael P. Hall,et al.  Characterization of the co‐elution of host cell proteins with monoclonal antibodies during protein A purification , 2016, Biotechnology progress.

[5]  Y. Taniguchi,et al.  Promotion of insulin aggregation by protein disulfide isomerase. , 2007, Biochimica et biophysica acta.

[6]  W. Epstein,et al.  Purification and immunohistochemical localization of aspartic proteinases in rat epidermis. , 1993, The Journal of investigative dermatology.

[7]  Hervé Broly,et al.  Degradation of an Fc‐fusion recombinant protein by host cell proteases: Identification of a CHO cathepsin D protease , 2009, Biotechnology and bioengineering.

[8]  W. Hancock,et al.  Characterization of the proteases involved in the N‐terminal clipping of glucagon‐like‐peptide‐1‐antibody fusion proteins , 2011, Biotechnology progress.

[9]  Abraham M Lenhoff,et al.  Identification and characterization of host cell protein product‐associated impurities in monoclonal antibody bioprocessing , 2014, Biotechnology and bioengineering.

[10]  P. Wright,et al.  Quantitative definition and monitoring of the host cell protein proteome using iTRAQ – a study of an industrial mAb producing CHO‐S cell line , 2016, Biotechnology journal.

[11]  Liu Tie,et al.  Trace levels of the CHO host cell protease cathepsin D caused particle formation in a monoclonal antibody product , 2015, Biotechnology progress.

[12]  S. Singh,et al.  Impact of product-related factors on immunogenicity of biotherapeutics. , 2011, Journal of pharmaceutical sciences.

[13]  Abraham M. Lenhoff,et al.  Expression of difficult‐to‐remove host cell protein impurities during extended Chinese hamster ovary cell culture and their impact on continuous bioprocessing , 2015, Biotechnology and bioengineering.

[14]  Cathy H. Wu,et al.  The Universal Protein Resource (UniProt) , 2004, Nucleic Acids Res..

[15]  N. Xu,et al.  Proteolytic Characteristics of Cathepsin D Related to the Recognition and Cleavage of Its Target Proteins , 2013, PloS one.

[16]  Shujun Bai,et al.  Fragmentation of a highly purified monoclonal antibody attributed to residual CHO cell protease activity. , 2011, Biotechnology and bioengineering.

[17]  Steven R Labrenz,et al.  Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations. , 2014, Journal of pharmaceutical sciences.